{"hands_on_practices": [{"introduction": "In clinical practice, diagnosing Group A Streptococcus (GAS) pharyngitis based on symptoms alone is fraught with uncertainty. This exercise demonstrates how to formalize clinical judgment by applying Bayes' theorem, a cornerstone of medical diagnostics. You will learn to use likelihood ratios associated with the Centor score criteria to transform a general community prevalence into a patient-specific posterior probability of infection, providing a quantitative basis for the decision to test or treat [@problem_id:4695178].", "problem": "A clinician evaluating an adult with acute pharyngitis is concerned about Group A Streptococcus (GAS; Streptococcus pyogenes) infection due to the potential for immune-mediated sequelae such as acute rheumatic fever and post-streptococcal glomerulonephritis. The patient has a Centor score of $4$, meaning all four criteria are present: tonsillar exudates, tender anterior cervical lymphadenopathy, history of fever, and absence of cough. Assume a pre-test prevalence (interpreted as pre-test probability) of GAS in the community of $0.30$. Under the assumption that, conditional on disease status, the Centor criteria contribute independently to the diagnostic evidence, use Bayes theorem and the definition of the likelihood ratio to compute the posterior probability of GAS infection when all four criteria are positive. For the individual likelihood ratios (positive) of each criterion, use the following values, which are consistent with meta-analytic estimates in adult populations:\n\n- Tonsillar exudates: $\\text{LR}^{+} = 2.5$\n- Tender anterior cervical lymphadenopathy: $\\text{LR}^{+} = 1.7$\n- History of fever: $\\text{LR}^{+} = 1.5$\n- Absence of cough: $\\text{LR}^{+} = 1.3$\n\nExpress your final answer as a decimal probability and round to four significant figures. Do not use a percentage sign.", "solution": "The problem is valid. It is a well-posed application of Bayesian inference in a standard clinical diagnostic scenario, using established concepts such as pre-test probability and likelihood ratios. All necessary data and assumptions are provided.\n\nThe objective is to calculate the posterior probability of a Group A Streptococcus (GAS) infection given that all four Centor criteria are present. We will use Bayes' theorem, conveniently expressed in its odds-likelihood form.\n\nLet $D$ be the event that the patient has a GAS infection. The problem provides the pre-test prevalence, which we interpret as the pre-test probability $P(D)$.\n$$P(D) = 0.30$$\nThe pre-test odds of infection, $O(D)$, are given by the ratio of the probability of the event to the probability of its complement:\n$$O(D) = \\frac{P(D)}{1 - P(D)}$$\nSubstituting the given value:\n$$O(D) = \\frac{0.30}{1 - 0.30} = \\frac{0.30}{0.70} = \\frac{3}{7}$$\nLet $E$ denote the collected evidence, which is that all four Centor criteria are positive. We are tasked with finding the posterior probability of disease given this evidence, $P(D|E)$.\n\nBayes' theorem in odds form states that the posterior odds are the product of the prior odds and the likelihood ratio (LR) of the evidence:\n$$O(D|E) = O(D) \\times \\text{LR}^{+}(E)$$\nHere, $\\text{LR}^{+}(E)$ is the positive likelihood ratio for the combined set of evidence $E$.\n\nThe problem states that, conditional on disease status, the Centor criteria contribute independently. This critical assumption allows us to calculate the combined likelihood ratio by multiplying the individual likelihood ratios for each positive criterion. The given individual positive likelihood ratios ($\\text{LR}^{+}$) are:\n- Tonsillar exudates: $\\text{LR}^{+}_{1} = 2.5$\n- Tender anterior cervical lymphadenopathy: $\\text{LR}^{+}_{2} = 1.7$\n- History of fever: $\\text{LR}^{+}_{3} = 1.5$\n- Absence of cough: $\\text{LR}^{+}_{4} = 1.3$\n\nThe combined likelihood ratio is therefore:\n$$\\text{LR}^{+}(E) = \\text{LR}^{+}_{1} \\times \\text{LR}^{+}_{2} \\times \\text{LR}^{+}_{3} \\times \\text{LR}^{+}_{4}$$\n$$\\text{LR}^{+}(E) = 2.5 \\times 1.7 \\times 1.5 \\times 1.3$$\nPerforming the multiplication:\n$$\\text{LR}^{+}(E) = 8.2875$$\nNow we can calculate the posterior odds of infection:\n$$O(D|E) = O(D) \\times \\text{LR}^{+}(E) = \\frac{3}{7} \\times 8.2875$$\n$$O(D|E) = \\frac{24.8625}{7} \\approx 3.5517857$$\nFinally, we convert the posterior odds back to a probability using the relationship:\n$$P(D|E) = \\frac{O(D|E)}{1 + O(D|E)}$$\nSubstituting the value for the posterior odds:\n$$P(D|E) = \\frac{\\frac{24.8625}{7}}{1 + \\frac{24.8625}{7}} = \\frac{24.8625}{7 + 24.8625} = \\frac{24.8625}{31.8625}$$\nCalculating the numerical value:\n$$P(D|E) \\approx 0.780305...$$\nThe problem requires the answer to be rounded to four significant figures. The fifth significant figure is $0$, so we round down.\n$$P(D|E) \\approx 0.7803$$\nThis is the posterior probability of the patient having GAS pharyngitis, given a Centor score of $4$ and the specified pre-test probability and likelihood ratios.", "answer": "$$\\boxed{0.7803}$$", "id": "4695178"}, {"introduction": "The prevention of acute rheumatic fever (ARF) hinges on the timely administration of antibiotics, creating a literal race against the patient's own immune response. This problem models this critical public health challenge as a probabilistic competition between two processes: the time to treatment and the time to the initiation of the autoimmune cascade. By deriving the effectiveness of a treatment program from first principles, you will gain insight into how epidemiological models can quantify the population-level impact of clinical interventions and the importance of prompt healthcare access [@problem_id:4695406].", "problem": "Consider a season with a cohort of $N$ new symptomatic pharyngitis cases caused by Group A Streptococcus (Streptococcus pyogenes). In the absence of antibiotic treatment, the baseline probability of progressing to Acute Rheumatic Fever (ARF) per pharyngitis case is $r_{0}$. A fraction $c$ of cases receives an appropriate antibiotic that, once given, fully abrogates the progression to ARF provided it is administered before the individualâ€™s immune cascade would have initiated ARF. Let $T$ denote the time from symptom onset to the initiation of the ARF-triggering immune cascade among those who would progress without treatment, and let $\\tau$ denote the time from symptom onset to antibiotic initiation among treated individuals. Assume the following:\n- The random variable $T$ has an exponential distribution with rate parameter $\\alpha$ ($\\text{day}^{-1}$) among those who would have progressed to ARF, reflecting a memoryless initiation of the pathological immune cascade.\n- The random variable $\\tau$ has an exponential distribution with rate parameter $\\beta$ ($\\text{day}^{-1}$) among treated individuals, reflecting a memoryless time-to-treatment process.\n- The variables $T$ and $\\tau$ are independent.\n- ARF progression is fully prevented if and only if antibiotic treatment occurs before ARF initiation in that individual, that is, when $\\tau < T$; otherwise, ARF is not prevented.\n\nFrom first principles of probability, derive the expected number of ARF cases prevented in the cohort and evaluate it for the following scientifically plausible parameters:\n- $N = 2.0 \\times 10^{5}$ cases,\n- $c = 0.70$,\n- $r_{0} = 0.018$,\n- $\\alpha = \\frac{1}{21}\\text{ day}^{-1}$,\n- $\\beta = 0.40\\text{ day}^{-1}$.\n\nExpress the final expected count as a number of cases and round your answer to four significant figures.", "solution": "The problem is deemed valid as it is scientifically grounded, well-posed, and objective. It is based on established principles of infectious disease epidemiology and probability theory, provides a complete and consistent set of data and conditions, and is free of ambiguity or subjective claims.\n\nThe objective is to calculate the expected number of Acute Rheumatic Fever (ARF) cases prevented in a cohort of patients with Group A Streptococcus (GAS) pharyngitis. Let this quantity be denoted by $E[\\text{Prevented}]$.\n\nFirst, we identify the key parameters and variables provided:\n- The total number of pharyngitis cases in the cohort is $N = 2.0 \\times 10^{5}$.\n- The fraction of cases receiving antibiotic treatment is $c = 0.70$.\n- The baseline probability of a single untreated case progressing to ARF is $r_{0} = 0.018$.\n- The time $T$ to ARF initiation is an exponential random variable with rate $\\alpha = \\frac{1}{21}\\text{ day}^{-1}$.\n- The time $\\tau$ to antibiotic administration is an exponential random variable with rate $\\beta = 0.40\\text{ day}^{-1}$.\n- The random variables $T$ and $\\tau$ are independent.\n\nAn ARF case is prevented in an individual if three conditions are met simultaneously:\n1. The individual is among those who would have developed ARF in the absence of treatment.\n2. The individual receives antibiotic treatment.\n3. The treatment is administered before the immune cascade initiates ARF, i.e., $\\tau < T$.\n\nLet us determine the expected number of individuals who satisfy the first two conditions. The total cohort size is $N$. The number of individuals who receive treatment is $N \\times c$. Within this treated group, the expected number of individuals who were \"destined\" to develop ARF (based on the baseline risk $r_{0}$) is the size of the treated group multiplied by the baseline probability, which is $(N \\times c) \\times r_{0}$. This product, $N c r_{0}$, represents the maximum possible number of ARF cases that can be prevented by the treatment program.\n\nFor each of these $N c r_{0}$ individuals, prevention is successful only if the treatment is timely, meaning $\\tau < T$. The probability of this event, $P(\\tau < T)$, must be calculated. Since $T$ and $\\tau$ are independent exponential random variables, we can find this probability by integrating their joint probability density function, $f_{T,\\tau}(t, s) = f_T(t)f_\\tau(s)$, over the region where $s < t$.\n\nThe probability density function (PDF) for $T$ is $f_T(t) = \\alpha \\exp(-\\alpha t)$ for $t \\ge 0$.\nThe PDF for $\\tau$ is $f_\\tau(s) = \\beta \\exp(-\\beta s)$ for $s \\ge 0$.\nThe joint PDF is $f_{T,\\tau}(t, s) = \\alpha \\beta \\exp(-\\alpha t - \\beta s)$ for $t, s \\ge 0$.\n\nThe probability $P(\\tau < T)$ is calculated as follows:\n$$ P(\\tau < T) = \\int_{t=0}^{\\infty} \\int_{s=0}^{t} f_{T,\\tau}(t, s) \\, ds \\, dt $$\n$$ P(\\tau < T) = \\int_{t=0}^{\\infty} \\int_{s=0}^{t} \\alpha \\beta \\exp(-\\alpha t) \\exp(-\\beta s) \\, ds \\, dt $$\nFirst, we evaluate the inner integral with respect to $s$:\n$$ \\int_{s=0}^{t} \\beta \\exp(-\\beta s) \\, ds = [-\\exp(-\\beta s)]_{s=0}^{t} = (-\\exp(-\\beta t)) - (-\\exp(0)) = 1 - \\exp(-\\beta t) $$\nNext, we substitute this result into the outer integral:\n$$ P(\\tau < T) = \\int_{t=0}^{\\infty} \\alpha \\exp(-\\alpha t) (1 - \\exp(-\\beta t)) \\, dt $$\n$$ P(\\tau < T) = \\int_{t=0}^{\\infty} (\\alpha \\exp(-\\alpha t) - \\alpha \\exp(-(\\alpha + \\beta)t)) \\, dt $$\nThis integral can be split into two parts:\n$$ \\int_{0}^{\\infty} \\alpha \\exp(-\\alpha t) \\, dt - \\int_{0}^{\\infty} \\alpha \\exp(-(\\alpha + \\beta)t) \\, dt $$\nThe first integral is the total probability of the exponential distribution for $T$, which equals $1$. For the second integral:\n$$ \\alpha \\int_{0}^{\\infty} \\exp(-(\\alpha + \\beta)t) \\, dt = \\alpha \\left[ \\frac{-\\exp(-(\\alpha + \\beta)t)}{\\alpha + \\beta} \\right]_{t=0}^{\\infty} = \\alpha \\left( 0 - \\frac{-1}{\\alpha + \\beta} \\right) = \\frac{\\alpha}{\\alpha + \\beta} $$\nTherefore, the probability of successful prevention is:\n$$ P(\\tau < T) = 1 - \\frac{\\alpha}{\\alpha + \\beta} = \\frac{(\\alpha + \\beta) - \\alpha}{\\alpha + \\beta} = \\frac{\\beta}{\\alpha + \\beta} $$\nThe expected number of prevented ARF cases, $E[\\text{Prevented}]$, is the expected number of at-risk treated individuals multiplied by the probability of successful prevention for each:\n$$ E[\\text{Prevented}] = (N c r_{0}) \\times P(\\tau < T) = N c r_{0} \\frac{\\beta}{\\alpha + \\beta} $$\nNow, we substitute the given numerical values:\n$N = 2.0 \\times 10^{5}$\n$c = 0.70$\n$r_{0} = 0.018$\n$\\alpha = \\frac{1}{21}\\text{ day}^{-1}$\n$\\beta = 0.40\\text{ day}^{-1}$\n\nFirst, calculate the probability term $\\frac{\\beta}{\\alpha + \\beta}$:\n$$ \\alpha + \\beta = \\frac{1}{21} + 0.40 = \\frac{1}{21} + \\frac{4}{10} = \\frac{1}{21} + \\frac{2}{5} = \\frac{5 \\times 1 + 2 \\times 21}{105} = \\frac{5 + 42}{105} = \\frac{47}{105} $$\n$$ \\frac{\\beta}{\\alpha + \\beta} = \\frac{0.40}{\\frac{47}{105}} = \\frac{2/5}{47/105} = \\frac{2}{5} \\times \\frac{105}{47} = \\frac{2 \\times 21}{47} = \\frac{42}{47} $$\nNext, calculate the term $N c r_{0}$:\n$$ N c r_{0} = (2.0 \\times 10^{5}) \\times 0.70 \\times 0.018 = 1.4 \\times 10^{5} \\times 0.018 = 2520 $$\nFinally, compute the expected number of prevented cases:\n$$ E[\\text{Prevented}] = 2520 \\times \\frac{42}{47} = \\frac{105840}{47} \\approx 2251.91489... $$\nThe problem requires the answer to be rounded to four significant figures. Rounding $2251.91489...$ to four significant figures gives $2252$. Expressing this in standard scientific notation yields $2.252 \\times 10^3$.", "answer": "$$\\boxed{2.252 \\times 10^3}$$", "id": "4695406"}, {"introduction": "A major obstacle in developing a vaccine for *Streptococcus pyogenes* is the risk of inducing the very autoimmunity we seek to prevent, due to molecular mimicry between bacterial and human proteins. This advanced exercise places you in the role of a vaccine designer, tasked with creating a computational risk assessment model from the ground up. By integrating multiple immunoinformatics features into a Bayesian framework, you will practice the data-driven methods used to identify and exclude potentially cross-reactive epitopes, ensuring the safety of next-generation vaccine candidates [@problem_id:4695267].", "problem": "You are tasked with modeling the risk of autoimmunity arising from molecular mimicry between epitopes from Streptococcus pyogenes and structurally similar regions in human proteins, which is a well-studied mechanism underlying immune sequelae such as rheumatic heart disease. Consider the following principles and definitions as the fundamental base for your derivation: immune sequelae can be initiated when adaptive immune responses, shaped by pathogen epitopes, cross-react with host proteins due to sequence and structural similarity; the probability of such cross-reactivity increases monotonically with similarity and immunogenicity; and Bayes' theorem relates prior odds, likelihood ratios, and posterior odds. You must derive a principled, monotonic mapping from feature-level similarity and immunogenicity variables to a posterior risk index for autoimmunity and then make a decision about excluding epitopes from vaccine candidates based on a threshold.\n\nDefinitions and modeling assumptions to use:\n- Let the risk index be the posterior probability of harmful cross-reactive activation, denoted by $p$, computed from a baseline prior probability $p_0$ and a likelihood ratio $\\mathrm{LR}$ derived from feature contributions. The posterior odds are the prior odds multiplied by $\\mathrm{LR}$, and the posterior probability is the odds converted to probability.\n- Features per epitope:\n  - Structural alignment score $s \\in [0,1]$ (unitless), where higher values indicate greater structural similarity to a human protein region.\n  - Sequence identity fraction $q \\in [0,1]$ (unitless).\n  - Normalized solvent accessibility $e \\in [0,1]$ (unitless), representing exposure relevant to B-cell recognition.\n  - Predicted Human Leukocyte Antigen (HLA) binding affinity $IC_{50}$ in nanomolar (nM), which you must transform into a dimensionless T-cell immunogenicity factor $m \\in [0,1]$ using a monotonic mapping.\n  - Epitope conservation across Streptococcus pyogenes strains $c \\in [0,1]$ (unitless).\n- Use a log-linear model for the likelihood ratio that is consistent with monotonicity and the exponential family, with fixed weights that encode the relative importance of each feature and their interaction. The weights are given as constants: $b_0 = 0$, $b_s = 1.5$, $b_q = 1.0$, $b_e = 0.5$, $b_m = 1.2$, $b_c = 0.8$, and $b_{sq} = 0.6$. The baseline prior is $p_0 = 0.01$.\n- Use a half-saturation constant $K = 50\\,\\mathrm{nM}$ in your monotonic mapping from $IC_{50}$ to $m$.\n- Decision rule: exclude an epitope if its computed risk index $p$ is greater than or equal to the threshold $\\tau = 0.2$. Express the risk index as a decimal in $[0,1]$.\n\nYour program must implement the following steps for each test case:\n1. Compute $m$ from $IC_{50}$ using a monotonic transformation that maps lower $IC_{50}$ to higher $m$ and ensures $m \\in [0,1]$.\n2. Compute the likelihood ratio $\\mathrm{LR}$ from the features using the specified weights and an interaction term between structural and sequence similarity.\n3. Convert prior probability $p_0$ and $\\mathrm{LR}$ to a posterior probability $p$ using Bayes' theorem.\n4. Apply the decision rule using $\\tau$ to produce a boolean exclusion decision.\n\nTest suite (each test case is a tuple $(s, q, e, IC_{50}, c)$):\n- Case $1$: $s = 0.6$, $q = 0.55$, $e = 0.8$, $IC_{50} = 30$, $c = 0.9$.\n- Case $2$: $s = 0.2$, $q = 0.1$, $e = 0.5$, $IC_{50} = 500$, $c = 0.4$.\n- Case $3$: $s = 0.9$, $q = 0.35$, $e = 0.3$, $IC_{50} = 20$, $c = 0.7$.\n- Case $4$: $s = 0.75$, $q = 0.5$, $e = 0.6$, $IC_{50} = 50$, $c = 0.5$.\n- Case $5$: $s = 1.0$, $q = 0.8$, $e = 0.9$, $IC_{50} = 10$, $c = 1.0$.\n- Case $6$: $s = 0.05$, $q = 0.0$, $e = 0.1$, $IC_{50} = 5$, $c = 0.2$.\n\nAngle units are not applicable. No physical units are required for the final output. You must express the risk index as a decimal fraction in $[0,1]$ rounded to four decimal places. Your program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets. Each item corresponds to one test case and must itself be a two-element list consisting of the rounded risk index and the boolean decision, for example, $[[0.1234,\\mathrm{False}],[0.5678,\\mathrm{True}],\\ldots]$.", "solution": "The problem statement is deemed valid. It is scientifically grounded in established principles of immunoinformatics and statistics, is well-posed with a clear and complete set of definitions, data, and constraints, and is expressed in objective, formal language. All necessary information is provided to derive a unique, verifiable solution for each test case.\n\nThe task is to compute a risk index for autoimmunity, $p$, for given *Streptococcus pyogenes* epitopes and decide on their exclusion from a vaccine candidate based on this risk. The derivation follows a sequence of principled steps, starting from raw features and culminating in a probabilistic risk assessment.\n\n**Step 1: Compute the T-cell Immunogenicity Factor ($m$)**\n\nThe problem requires a monotonic mapping from the predicted Human Leukocyte Antigen (HLA) binding affinity, $IC_{50}$ (in units of nM), to a dimensionless T-cell immunogenicity factor, $m \\in [0,1]$. A lower $IC_{50}$ value signifies stronger binding and thus higher immunogenicity. This inverse relationship is modeled using a function analogous to the Hill-Langmuir equation, incorporating the given half-saturation constant $K = 50\\,\\mathrm{nM}$. The value of $m$ is determined by the equation:\n$$\nm = \\frac{K}{K + IC_{50}}\n$$\nSubstituting the given value of $K$:\n$$\nm = \\frac{50}{50 + IC_{50}}\n$$\nThis function correctly ensures that as $IC_{50} \\to 0$, $m \\to 1$ (maximum immunogenicity), and as $IC_{50} \\to \\infty$, $m \\to 0$ (negligible immunogenicity). At $IC_{50} = K = 50$, we have $m=0.5$.\n\n**Step 2: Compute the Likelihood Ratio ($\\mathrm{LR}$)**\n\nThe problem specifies a log-linear model to aggregate the contributions of various features into a likelihood ratio, $\\mathrm{LR}$. This model synthesizes evidence from structural similarity ($s$), sequence identity ($q$), solvent accessibility ($e$), immunogenicity ($m$), and conservation ($c$). The natural logarithm of the likelihood ratio is a weighted sum of these features, including an interaction term between structure and sequence similarity:\n$$\n\\ln(\\mathrm{LR}) = b_0 + b_s s + b_q q + b_e e + b_m m + b_c c + b_{sq} (s \\cdot q)\n$$\nThe likelihood ratio itself is obtained by exponentiating this expression:\n$$\n\\mathrm{LR} = \\exp\\left( b_0 + b_s s + b_q q + b_e e + b_m m + b_c c + b_{sq} (s \\cdot q) \\right)\n$$\nThe provided weights are: $b_0 = 0$, $b_s = 1.5$, $b_q = 1.0$, $b_e = 0.5$, $b_m = 1.2$, $b_c = 0.8$, and $b_{sq} = 0.6$. Substituting these values and noting that $b_0=0$ simplifies the equation:\n$$\n\\mathrm{LR} = \\exp\\left( 1.5 s + 1.0 q + 0.5 e + 1.2 m + 0.8 c + 0.6 s q \\right)\n$$\n\n**Step 3: Compute the Posterior Probability of Risk ($p$)**\n\nBayes' theorem is used to update the prior probability of risk, $p_0$, to a posterior probability, $p$, given the evidence encapsulated in the likelihood ratio, $\\mathrm{LR}$. The theorem is most conveniently applied in terms of odds.\n\nThe prior odds of harmful cross-reactive activation are defined as:\n$$\n\\text{Odds}_0 = \\frac{p_0}{1 - p_0}\n$$\nGiven the baseline prior probability $p_0 = 0.01$, the prior odds are:\n$$\n\\text{Odds}_0 = \\frac{0.01}{1 - 0.01} = \\frac{0.01}{0.99} = \\frac{1}{99}\n$$\nThe posterior odds, $\\text{Odds}_p$, are the product of the prior odds and the likelihood ratio:\n$$\n\\text{Odds}_p = \\text{Odds}_0 \\times \\mathrm{LR}\n$$\nFinally, the posterior probability $p$ (the risk index) is recovered from the posterior odds:\n$$\np = \\frac{\\text{Odds}_p}{1 + \\text{Odds}_p}\n$$\n\n**Step 4: Apply the Decision Rule**\n\nAn epitope is excluded from a vaccine candidate if its computed risk index $p$ is greater than or equal to a specified threshold, $\\tau$. The decision rule is:\n$$\n\\text{Decision} = \\begin{cases} \\text{True (Exclude)} & \\text{if } p \\ge \\tau \\\\ \\text{False (Include)} & \\text{if } p < \\tau \\end{cases}\n$$\nThe given threshold is $\\tau = 0.2$.\n\n**Example Calculation for Case 1**\n\nFor Case 1, the feature values are: $s = 0.6$, $q = 0.55$, $e = 0.8$, $IC_{50} = 30$, and $c = 0.9$.\n\n1.  **Compute $m$**:\n    $$\n    m = \\frac{50}{50 + 30} = \\frac{50}{80} = 0.625\n    $$\n2.  **Compute $\\mathrm{LR}$**:\n    $$\n    \\ln(\\mathrm{LR}) = (1.5 \\times 0.6) + (1.0 \\times 0.55) + (0.5 \\times 0.8) + (1.2 \\times 0.625) + (0.8 \\times 0.9) + (0.6 \\times 0.6 \\times 0.55)\n    $$\n    $$\n    \\ln(\\mathrm{LR}) = 0.9 + 0.55 + 0.4 + 0.75 + 0.72 + 0.198 = 3.518\n    $$\n    $$\n    \\mathrm{LR} = \\exp(3.518) \\approx 33.7171\n    $$\n3.  **Compute $p$**:\n    $$\n    \\text{Odds}_p = \\frac{1}{99} \\times 33.7171 \\approx 0.340577\n    $$\n    $$\n    p = \\frac{0.340577}{1 + 0.340577} \\approx 0.25405\n    $$\n    Rounding to four decimal places, the risk index is $p \\approx 0.2541$.\n4.  **Apply Decision Rule**:\n    Since $p \\approx 0.2541$ and $\\tau = 0.2$, we have $0.2541 \\ge 0.2$. The decision is `True` (Exclude).\n\nThe same procedure is applied to all other test cases to generate the final results.", "answer": "```\n[[0.2541,True],[0.0292,False],[0.2829,True],[0.1908,False],[0.7099,True],[0.0768,False]]\n```", "id": "4695267"}]}